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BACKGROUND: High-sensitivity cardiac troponin assays can help to 
identify patients who are at low risk of myocardial infarction in the 
emergency department. We aimed to determine whether the addition of 
clinical risk scores would improve the safety of early rule-out pathways for 
myocardial infarction.
METHODS: In 1935 patients with suspected acute coronary syndrome, 
we evaluated the safety and efficacy of 2 rule-out pathways alone or in 
conjunction with low-risk TIMI (Thrombolysis In Myocardial Infarction) (0 
or 1), GRACE (Global Registry of Acute Coronary Events) (≤108), EDACS 
(Emergency Department Assessment of Chest Pain Score) (<16), or HEART 
(History, ECG, Age, Risk factors, Troponin) (≤3) scores. The European 
Society of Cardiology 3-hour pathway uses a single diagnostic threshold 
(99th percentile), whereas the High-STEACS (High-Sensitivity Troponin 
in the Evaluation of Patients With Acute Coronary Syndrome) pathway 
applies different thresholds to rule out (<5 ng/L) and rule in (>99th 
percentile) myocardial infarction.
RESULTS: Myocardial infarction or cardiac death during the index 
presentation or at 30 days occurred in 14.3% of patients (276/1935). The 
European Society of Cardiology pathway ruled out 70%, with 27 missed 
events giving a negative predictive value of 97.9% (95% CI, 97.1–98.6). 
The addition of a HEART score ≤3 reduced the proportion ruled out 
by the European Society of Cardiology pathway to 25% but improved 
the negative predictive value to 99.7% (95% CI, 99.0–100; P<0.001). 
The High-STEACS pathway ruled out 65%, with 3 missed events for a 
negative predictive value of 99.7% (95% CI, 99.4–99.9). No risk score 
improved the negative predictive value of the High-STEACS pathways, but 
all reduced the proportion ruled out (24% to 47%; P<0.001 for all).
CONCLUSIONS: Clinical risk scores significantly improved the safety of 
the European Society of Cardiology 3-hour pathway, which relies on a 
single cardiac troponin threshold at the 99th percentile to rule in and rule 
out myocardial infarction. Where lower thresholds are used to rule out 
myocardial infarction, as applied in the High-STEACS pathway, risk scores 
halve the proportion of patients ruled out without improving safety.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. 
Unique identifier: NCT01852123.
© 2018 The Authors. Circulation is 
published on behalf of the American 
Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of the 
Creative Commons Attribution License, 
which permits use, distribution, and 
reproduction in any medium, provided 
that the original work is properly cited.
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Chest pain is a common presenting symptom in the emergency department, and although many patients require investigation for acute coronary 
syndrome, the majority have alternative diagnoses.1–3 
Earlier identification of patients without myocardial in-
farction may improve patient experience and healthcare 
efficiency by reducing hospitalization for unnecessary 
investigation, but such strategies can only be imple-
mented if safety is not compromised.
Several pathways permit the early rule-out of myo-
cardial infarction. The European Society of Cardiology 
(ESC) 3-hour pathway uses the 99th percentile upper 
reference limit of a cardiac troponin assay to rule in and 
rule out myocardial infarction.4 However, recent obser-
vations have questioned whether this pathway provides 
adequate diagnostic performance in the era of high-
sensitivity cardiac troponin testing.5–7 The precision of 
high-sensitivity assays at low concentrations has been 
exploited in the development of novel pathways that 
rule out myocardial infarction using thresholds <99th 
percentile. In an individual patient-level data meta-anal-
ysis of 22 457 patients, a cardiac troponin I threshold of 
<5 ng/L and a nonischemic ECG gave a negative pre-
dictive value (NPV) and sensitivity of 99.7% and 99.0% 
for myocardial infarction or cardiac death at 30 days, 
respectively.8 The same threshold has also been validat-
ed for the high-sensitivity cardiac troponin T assay in a 
recent pooled analysis.9 When this rule-out threshold 
was applied in a pathway that includes serial testing at 
0 and 3 hours, 5-fold fewer patients were missed com-
pared with a pathway that relies on the 99th percentile 
to rule out myocardial infarction.6
Clinical risk scores provide an alternative approach 
to identify patients at low risk of myocardial infarction 
who might be suitable for early discharge, but a num-
ber of uncertainties remain.10 New risk scores were de-
veloped11 or existing scores were incorporated into early 
rule-out pathways primarily to overcome the limitations 
of contemporary troponin assays.12 However, the role 
of clinical risk scores in pathways that incorporate high-
sensitivity cardiac troponin testing is unclear, particu-
larly in those pathways that apply different thresholds 
to rule out and rule in myocardial infarction. Here, we 
evaluate the safety and effectiveness of established ear-
ly rule-out pathways with and without the addition of 
clinical risk scores.
METHODS
Transparency and Openness Promotion
The analysis code for this study is available on request. Data 
can be made available to other researchers for the purposes 
of reproducing the results with a data sharing agreement.
Study Population
Patients with suspected acute coronary syndrome were 
recruited from the emergency department of the Royal 
Infirmary of Edinburgh, a tertiary care hospital in Scotland, 
between June 1, 2013, and March 31, 2017, into a sub-
study of the High-STEACS trial (High-Sensitivity Troponin in 
the Evaluation of Patients With Acute Coronary Syndrome). 
All patients for whom the attending clinician requested 
cardiac troponin for suspected acute coronary syndrome 
were eligible for inclusion. We did not enroll patients with 
ST-segment elevation myocardial infarction, those who 
were unable to provide consent, or those from outside our 
region, to ensure complete follow-up. Blood samples were 
obtained at presentation and at 6 to 12 hours for high-
sensitivity cardiac troponin testing as part of routine clini-
cal care. Patients provided written informed consent for 
additional sampling at 3 hours, with the results of testing 
at this timepoint not used to guide patient care. This clini-
cal trial was registered, approved by the national research 
ethics committee, and conducted in accordance with the 
Declaration of Helsinki.
Clinical Perspective
What Is New?
• We evaluate established rule-out pathways using 
high-sensitivity cardiac troponin testing to risk-
stratify patients with suspected acute coronary 
syndrome and determine whether the addition of 
clinical risk scores (TIMI [Thrombolysis In Myocar-
dial Infarction], GRACE [Global Registry of Acute 
Coronary Events], EDACS [Emergency Department 
Assessment of Chest Pain Score], and HEART [His-
tory, ECG, Age, Risk factors, Troponin]) is of benefit.
• The European Society of Cardiology 3-hour path-
way missed >2 patients in every 100 tested, with 
safety markedly improved by inclusion of any 
risk score, all of which reduced the proportion of 
patients identified as low-risk.
• The High-STEACS (High-Sensitivity Troponin in the 
Evaluation of Patients With Acute Coronary Syn-
drome) pathway missed <1 in every 400 patients 
tested and did not benefit from the addition of 
clinical risk scores.
What Are the Clinical Implications?
• Clinicians should consider using a risk score if apply-
ing the European Society of Cardiology 3-hour 
pathway, which uses the 99th percentile to rule in 
and rule out myocardial infarction.
• Clinical risk scores do not improve the performance 
of pathways that apply low concentrations of car-
diac troponin to risk-stratify patients, such as the 
High-STEACS pathway or the European Society of 
Cardiology 1-hour pathway.
• A prospective randomized controlled trial evaluat-
ing implementation of the High-STEACS pathway 
will provide further evidence of safety and efficacy 
in clinical practice and is due to report in early 2019.
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High-Sensitivity Cardiac Troponin I Assay
The Abbott ARCHITECTSTAT high-sensitive cardiac troponin 
I assay (Abbott Laboratories) is a 2-step chemoluminescent 
assay with a limit of detection of 1.2 ng/L and coefficient of 
variation of <10% at 6 ng/L.13 This assay performance has 
been independently validated across multiple centers under 
routine laboratory working conditions, with a reported inter-
laboratory coefficient of variation of 12.6% at 3.5 ng/L across 
33 instruments.14 The upper reference limit 99th percentiles 
were determined in 4590 samples from healthy individu-
als as 16 ng/L for women and 34 ng/L in men,15 and from 
December 10, 2013, onward, these thresholds were used in 
clinical practice.
Baseline Characteristics
Patient baseline characteristics, including chest pain character-
istics, onset of symptoms, prior medical history, cardiovascular 
risk factors, medication, and clinical observations, in addition 
to investigations including serial 12-lead electrocardiography 
and cardiac imaging, were obtained from a dedicated case 
record form, patient questionnaire, and the electronic patient 
record (TrakCare, InterSystems). Hyperlipidemia or hyperten-
sion was defined as a history of the condition or by the use 
of lipid-lowering or antihypertensive therapies, respectively. 
Ischemic heart disease was defined as a history of angina, 
prior myocardial infarction, or prior coronary revascularization.
Diagnostic Adjudication
The final diagnosis was adjudicated for all patients by 2 
independent cardiologists, with consensus from a third car-
diologist where there was discrepancy after review of all 
clinical information, both noninvasive and invasive investiga-
tions and outcomes from presentation to 30 days. Patients 
were classified as having type 1 myocardial infarction, type 
2 myocardial infarction, or myocardial injury in accordance 
with the third universal definition of myocardial infarction 
as reported previously.4,14 Any high-sensitivity cardiac tropo-
nin I concentration above the sex-specific 99th percentile 
upper reference limit was considered evidence of myocar-
dial necrosis. Type 1 myocardial infarction was defined as 
myocardial necrosis in the context of a presentation with 
symptoms suggestive of acute coronary syndrome or evi-
dence of myocardial ischemia. Patients with symptoms or 
signs of myocardial ischemia because of increased oxygen 
demand or decreased supply (eg, tachyarrhythmia, hypo-
tension, or anemia) secondary to an alternative pathology 
and myocardial necrosis were classified as type 2 myocar-
dial infarction. Myocardial injury was defined as evidence of 
myocardial necrosis in the absence of any clinical features 
of myocardial ischemia. Further details of the adjudication 
process are available in the appendix in the online-only Data 
Supplement. Agreement for a diagnosis of type 1 myocar-
dial infarction was good (κ=0.77; 95% CI, 0.69–0.84).
Clinical Outcomes
The primary outcome was a composite of type 1 myocar-
dial infarction or cardiac death during index presentation 
or at 30 days. We used regional and national registries 
in addition to individual patient follow-up at 30 days to 
ensure that follow-up was complete for the entire study 
population. All subsequent events were adjudicated using 
the same approach as for the index presentation. TrakCare 
software application (InterSystems Corporation) is a 
regional electronic patient record system that provides data 
on all hospital admissions to both tertiary and secondary 
care hospitals in the southeast of Scotland. All in-hospi-
tal and community deaths are recorded in a comprehen-
sive national database, the General Register of Scotland. 
Cardiac death was defined as any death because of myo-
cardial infarction, arrhythmia, or heart failure (International 
Classification of Diseases, Tenth Revision, codes I20-25, 
I34-37, I42, I43, I46, and I48-51).
Clinical Pathways
We evaluated the safety and efficacy of the ESC 3-hour 
pathway and the High-STEACS pathway (Figure 1), with and 
without the addition of clinical risk scores, to rule out the 
composite outcome of index type 1 myocardial infarction 
and type 1 myocardial infarction or cardiac death at 30 days. 
These pathways were selected because they represent exam-
ples of approaches using troponin as a continuous variable or 
as a binary decision tool applying the 99th percentile alone. 
To improve generalizability, where samples were available, we 
also evaluated the ESC 1-hour pathway.
ESC 3-Hour Pathway
The ESC 3-hour pathway rules out myocardial infarction in 
patients without ischemia on the ECG where cardiac tro-
ponin concentrations are <99th percentile at presentation 
in patients with symptoms for >6 hours. In patients with 
symptoms for <6 hours, a second troponin measurement 
is performed 3 hours from presentation, with myocardial 
infarction ruled out if cardiac troponin remains <99th per-
centile or is >99th percentile without a significant change in 
concentration.4 Previously published guidance from the ESC 
Working Group on Acute Cardiac Care recommends use of a 
change in cardiac troponin concentration >50% of the 99th 
percentile upper reference limit at 3 hours, where the initial 
concentration is ≤99th percentile or >20% when the initial 
concentration was >99th percentile.16 The ESC pathway 
recommends a GRACE (Global Registry of Acute Coronary 
Events) score of <140 in those who are pain free as a final 
step before discharge.
High-STEACS Pathway
The derivation and validation of the High-STEACS pathway 
has been reported previously.6 This pathway was based on 
previous observations8,14 and utilizes a risk stratification 
threshold of 5 ng/L at presentation. Patients without myocar-
dial ischemia on the ECG and cardiac troponin concentrations 
<5 ng/L at presentation are considered low risk, with myocar-
dial infarction ruled out without further testing, unless they 
present early with symptom onset <2 hours from presenta-
tion where cardiac troponin is retested 3 hours after presen-
tation. Patients with cardiac troponin concentrations ≥5 ng/L 
at presentation are retested at 3 hours. Myocardial infarction 
is ruled out at 3 hours if cardiac troponin concentrations are 
unchanged (∆ <3 ng/L) and remain ≤99th percentile.
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ESC 1-Hour Pathway
The ESC 1-hour pathway rules out myocardial infarction 
in patients without ischemia on the ECG where cardiac 
troponin concentrations are <2 ng/L at presentation and 
symptoms are present for >3 hours. In all other patients, 
myocardial infarction is ruled out if cardiac troponin con-
centrations are <5 ng/L at presentation with a change of <2 
ng/L after 1 hour.16
Clinical Risk Scores
We derived GRACE, TIMI (Thrombolysis In Myocardial 
Infarction), HEART (History, ECG, Age, Risk factors, 
Troponin), and EDACS (Emergency Department Assessment 
of Chest Pain Score) scores using prospectively collected 
clinical information documented in the case record form 
by the research nurse at the time of recruitment (Figure 2). 
We calculated the GRACE score for in-hospital death; this 
algorithm is available online.17 In line with prior recom-
mendations, a GRACE score of ≤108 (estimated in-hospital 
mortality of <1%),18 a HEART score of ≤3,11 a TIMI score 
of 0 or 1,19 or an EDACS score of <16 was considered 
low-risk.20 For comparison, we provide the diagnostic per-
formance of the HEART, GRACE, TIMI, and EDACS scores 
alone in the online-only Data Supplement.
Sensitivity Analyses
We evaluated the NPV of all approaches for a primary out-
come encompassing type 1 or type 2 myocardial infarction, 
myocardial injury, or cardiac death at 30 days. Because the 
High-STEACS pathway was derived in the first 1218 par-
ticipants included in our dataset, we repeated our analyses 
and excluded these subjects. In a further analysis, we tested 
both pathways, excluding any patients who underwent 
invasive or noninvasive cardiac testing in ≤30 days of index 
presentation.
Statistical Analysis
Baseline characteristics are summarized as mean (SD) or 
median (interquartile range) as appropriate. Where there were 
missing data for continuous variables, we imputed the median 
value. The primary outcome was the NPV of each pathway 
using the composite end point of index type 1 myocardial 
infarction, subsequent type 1 myocardial infarction, or car-
diac death at 30 days.14 Because we estimated the NPV would 
approach 100%, we used a Bayesian approach with a Jeffreys 
prior (β distribution with both shape parameters equal to 0.5); 
this is more robust when CIs approach 0 or 1.21 We determined 
absolute (hs-TnI3hr–hs-TnI0hr) and relative ([(hs-TnI3hr–hs-TnI0hr) / 
hs-TnI0hr]x100) change in cardiac troponin concentration from 
presentation to 3 hours and determined sensitivity, specificity, 
and positive predictive value with 95% CIs using a Bayesian 
approach as per the NPV. We derived a weighted general-
ized score statistic to compare the NPV of each pathway with 
and without the addition of clinical risk scores.22 We evalu-
ated pathway efficacy by determining the number of patients 
ruled out with the pathway alone or with the combination of 
pathway and risk score as a proportion of the total study pop-
ulation, with comparison by McNemar’s test for paired propor-
tions. A 2-sided P<0.05 was considered statistically significant. 
All analyses were performed using R (Version 3.2.2).
RESULTS
We enrolled 1951 patients with suspected acute coro-
nary syndrome, of whom 1935 had a cardiac troponin 
I result available from presentation (Tables 1 and 2 and 
Figure I in the online-only Data Supplement). The adjudi-
cated diagnosis was type 1 myocardial infarction in 273 
patients (14.1%), type 2 myocardial infarction in 77 pa-
tients (4%), and myocardial injury in 31 patients (1.6%), 
with 6 deaths from a cardiac cause at 30 days (Figure 3).
Figure 1. Illustration of the ESC 3-hour and High-STEACS pathways.  
ESC indicates European Society of Cardiology; F, female; High-STEACS, High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome; M, 
male; NPV, negative predictive value; and PPV, positive predictive value.
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ESC 3-Hour Pathway
A total of 1886 patients (97.5%) were included, with 49 
patients excluded because of missing 3-hour samples, 
which were required for the ESC pathway (Figure 1). The 
ESC pathway identified 70% (1328/1886) of patients as 
low-risk, with 27 missed events (25 index type 1 myo-
cardial infarction, 1 type 1 myocardial infarction, and 1 
cardiac death at 30 days) (Table I in the online-only Data 
Supplement) for a NPV of 97.9% (95% CI, 97.1–98.6) 
and sensitivity of 89.9% (95% CI, 86.3–93.4) (Table 3).
ESC 3-Hour Pathway Plus Risk Scores
When a HEART score of ≤3 was applied alongside the 
ESC pathway, the proportion identified as low-risk 
fell from 70% to 24.8% (468/1886, P<0.001). How-
ever, the NPV improved to 99.7% (95% CI, 99.0–100; 
P<0.001). A similar improvement in safety was observed 
when an EDACS score of <16 was applied, with an NPV 
of 99.2% (95% CI, 98.5–99.7; P<0.001), identifying 
42.4% as low-risk (800/1886, P<0.001). A TIMI score 
of 0 or 1 gave an NPV of 99.2% (95% CI, 98.5–99.7; 
P<0.001), and a GRACE score of ≤108 gave an NPV of 
99.0% (95% CI, 98.2–99.5; P<0.001), with a reduc-
tion in the proportion identified as low-risk to 43.5% 
(844/1886, P<0.001) and 49% (924/1886, P<0.001) of 
patients, respectively. When a higher GRACE score of 
<140 was applied as recommended in the guideline, 
the NPV and sensitivity were lower at 98.1% (95% CI, 
97.3–98.8) and 91.3% (95% CI, 87.8–94.4), respec-
tively, with 23 missed index or 30-day events.
High-STEACS Pathway
A total of 1917 patients (99.1%) were included, with 
18 patients excluded because of missing 3-hour sam-
ples, which were required for the High-STEACS pathway 
(Figure 1). The High-STEACS pathway identified 64.9% 
(1244/1917) of patients as low-risk, with 3 missed events 
(2 index type 1 myocardial infarction and 1 type 1 myocar-
dial infarction at 30 days) (Table II in the online-only Data 
Supplement) for an NPV of 99.7% (95% CI, 99.4–99.9) 
and sensitivity of 98.7% (95% CI, 97.4–99.8) (Table 4).
High-STEACS Pathway Plus Risk Scores
When a HEART score ≤3 was applied alongside the 
High-STEACS pathway, the proportion identified as 
low-risk fell to 24.3% (465/1917, P<0.001). There was 
no improvement in the NPV (99.9%; 95% CI, 99.6–
100; P=0.083). Similarly, no improvements in NPV were 
observed when the High-STEACS pathway was ap-
plied in conjunction with an EDACS score of <16 (NPV, 
99.7%; 95% CI, 99.2–99.9; P=0.912), a TIMI score of 
0 or 1 (NPV, 99.8%; 95% CI, 99.4–100; P=0.313), or a 
GRACE score of ≤108 (NPV, 99.7%; 95% CI, 99.3–100; 
P=0.815). All risk scores reduced the proportion of pa-
tients identified as low-risk (EDACS 41%, TIMI 44%, 
and GRACE 47%; P<0.001 for all) (Figure 4).
Sensitivity Analyses
We repeated our analyses of the High-STEACS and ESC 
3-hour pathways for a composite end point, including 
Figure 2. Components of the TIMI, GRACE, EDACS, and HEART clinical risk scores. 
The GRACE score algorithm is available online.17 BP indicates blood pressure; BPM, beats per minute; EDACS, Emergency Department Assessment of Chest Pain 
Score; GRACE, Global Registry of Acute Coronary Events; HEART, History, ECG, Age, Risk factors, Troponin; and TIMI, Thrombolysis In Myocardial Infarction.
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Table 1. Baseline Characteristics of the Study Population Stratified by Troponin Concentration
Variable All Patients (n=1935)
<5 ng/L at Presentation
(n=1142)
≤99th Percentile at 
Presentation (n=1639)
>99th Percentile at 
Presentation (n=296)
Baseline characteristics
  Age, y 61.5 (14.2) 56.6 (12.6) 60.2 (14) 68.7 (13.6)
  Male, % 1182 (61.1) 637 (55.8) 1012 (61.7) 170 (57.4)
  Chest pain, % 1623 (84.1) 983 (86.4) 1387 (84.9) 236 (79.9)
Symptom to arrival time, mins* 199 (118–464) 199 (114–462) 199 (115–445) 199 (138–528)
Past medical history
  Diabetes mellitus, % 286 (14.8) 124 (10.9) 229 (14.0) 57 (19.3)
  Hypertension, % 769 (39.7) 358 (31.3) 630 (38.4) 139 (47.0)
  Hyperlipidemia, % 765 (39.5) 376 (32.9) 641 (39.1) 124 (41.9)
  Family history, % 927 (47.9) 575 (50.4) 793 (48.4) 134 (45.3)
  Ischemic heart disease, % 582 (30.1) 252 (22.1) 484 (29.5) 98 (33.1)
  Previous MI, % 460 (23.8) 172 (15.1) 374 (22.8) 86 (29.1)
  Previous PCI, % 366 (18.9) 154 (13.5) 308 (18.8) 58 (19.6)
  Previous CABG, % 117 (6.0) 31 (2.7) 96 (5.9) 21 (7.1)
  Previous heart failure, % 66 (3.4) 10 (0.9) 45 (2.7) 21 (7.1)
  Previous stroke, % 119 (6.1) 45 (3.9) 97 (5.9) 22 (7.4)
  Smoker, % 385 (19.9) 266 (23.3) 330 (20.1) 55 (18.6)
Medication history
  Aspirin, % 655 (33.9) 305 (26.7) 545 (33.3) 110 (37.2)
  Clopidogrel, % 250 (12.9) 100 (8.8) 203 (12.4) 47 (15.9)
  β-Blocker, % 522 (27.0) 240 (21.0) 431 (26.3) 91 (30.7)
  ACE inhibitor, % 582 (30.1) 271 (23.7) 487 (29.7) 95 (32.1)
  Statin, % 824 (42.6) 398 (34.9) 690 (42.1) 134 (45.3)
  Long-acting nitrate, % 369 (19.1) 156 (13.7) 296 (18.1) 73 (24.7)
  Calcium channel blocker, % 242 (12.5) 109 (9.5) 199 (12.1) 43 (14.5)
  Warfarin (%) 105 (5.4) 34 (3.0) 83 (5.1) 22 (7.4)
ECG findings
  ST depression, % 112 (5.8) 27 (2.4) 65 (4.0) 47 (15.9)
  ST elevation, % 58 (3.0) 28 (2.5) 42 (2.6) 16 (5.4)
  T-wave inversion, % 300 (15.5) 113 (9.9) 218 (13.3) 82 (27.7)
Physiological parameters
  Systolic BP, mm Hg 137 (124–152) 137 (124–152) 137 (124–152) 137 (121–151)
  Diastolic BP, mm Hg 77 (68–88) 79 (70–89) 78 (69–88) 74 (66–85)
  Heart rate, bpm 75 (64–87) 75 (65–86) 75 (65–86) 76 (63–91)
  Temperature 36.5 (36.1–36.9) 36.5 (36.1–37) 36.5 (36.1–36.9) 36.5 (36–36.8)
  Respiratory rate 16 (16–18) 16 (16–18) 16 (16–18) 16 (16–18)
  Oxygen saturations 97 (96–98) 98 (96–99) 97 (96–99) 97 (96–98)
  Creatinine† 74 (67–84) 73 (66–78) 74 (67–82) 76 (69–94)
Clinical risk scores
  HEART 5 (3–6) 4 (3–5) 4 (3–5) 7 (6–8)
  GRACE 100 (79–107) 91 (79–100) 100 (79–129) 129 (107–151)
  TIMI 1 (0–3) 1 (0–2) 1 (0–2) 3 (2–4)
  EDACS 15 (10–19) 12 (8–16) 14 (9–19) 18 (14–23)
Adjudicated index diagnosis
  Type 1 myocardial infarction, % 273 (14.1) 6 (0.5) 65 (4.0) 208 (70.3)
(Continued )
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type 1 or type 2 myocardial infarction or myocardial in-
jury with similar performance observed (Tables III and IV 
in the online-only Data Supplement). Because the High-
STEACS pathway was derived in the first 1218 partici-
pants of this cohort study, we repeated our analyses and 
excluded these patients, with no differences observed in 
diagnostic performance (Table V in the online-only Data 
Supplement). In a further sensitivity analysis, we exclud-
ed any patients who underwent invasive or noninvasive 
cardiac testing and observed no differences in safety or 
efficacy (Table VI in the online-only Data Supplement). 
The diagnostic metrics for each risk score alone are pro-
vided in Table VII in the online-only Data Supplement.
ESC 1-Hour Rule-Out Pathway
Where samples were available at presentation and 1 
hour (406/1935), we evaluated the performance of the 
ESC 1-hour rule-out pathway (Table VIII in the online-
only Data Supplement). In this population, the preva-
lence of the primary outcome was 8.1% (33/406). The 
ESC 1-hour pathway identified 37.7% (153/406) of pa-
tients as low-risk at presentation and 71.4% (290/406) 
of patients as low-risk at 1 hour, with no missed cases, 
for an NPV of 99.8% (95% CI, 99.3–100) and sensi-
tivity of 98.5% (95% CI, 94.4–100). Because no cases 
were missed, no risk score improved safety, but all sig-
nificantly reduced the proportion identified as low-risk. 
When we applied the High-STEACS pathway in the 
subgroup of patients with 1-hour samples available, 
there were also no missed events.
DISCUSSION
In a prospective observational cohort study of patients 
with suspected acute coronary syndrome, we evalu-
ated the performance of high-sensitivity cardiac tropo-
nin testing in the ESC 3-hour pathway and the High-
STEACS pathway, which applies a lower threshold to 
rule out myocardial infarction with and without the 
  Type 2 myocardial infarction, % 77 (4.0) 5 (0.4) 24 (1.5) 53 (17.9)
  Myocardial injury, % 31 (1.6) 0 (0.0) 1 (0.1) 30 (10.1)
Outcomes at 30 days
  Type 1 myocardial infarction, %‡ 8 (0.4) 0 (0.0) 3 (0.2) 5 (1.7)
  Cardiac death at 30 days, % 6 (0.3) 0 (0.0) 2 (0.1) 4 (1.4)
  Type 1 myocardial infarction or 
cardiac death at 30 days, %§
276 (14.3) 6 (0.5) 68 (4.1) 208 (70.3)
Values are mean (SD), median (IQR), or n (%). ACE indicates angiotensin-converting enzyme; BP, blood pressure; CABG, coronary artery bypass grafting; 
EDACS, Emergency Department Assessment of Chest Pain Score; GRACE, Global Registry of Acute Coronary Events; HEART, History, ECG, Age, Risk factors, 
Troponin; IQR, interquartile range; MI, myocardial infarction; PCI , percutaneous coronary intervention; and TIMI, Thrombolysis In Myocardial Infarction. 
*Data missing in 10.4% (202/1935).
†Data missing in 10% (193/1935).
‡Excluding index events. 
§Only the first event counted.
Table 1. Continued
Variable All Patients (n=1935)
<5 ng/L at Presentation
(n=1142)
≤99th Percentile at 
Presentation (n=1639)
>99th Percentile at 
Presentation (n=296)
Table 2. Investigation and Management of Patients Stratified by Troponin Concentration at Presentation
Variable All Patients (n=1935)
<5 ng/L at 
Presentation (n=1142)
≤99th Percentile at 
Presentation (n=1639)
>99th Percentile at 
Presentation (n=296)
In-hospital management
  Aspirin, n (%) 1055 (56.3) 564 (50.9) 839 (52.9) 216 (74.7)
  Clopidogrel, n (%) 217 (11.9) 27 (2.5) 54 (3.5) 163 (57.2)
  Ticagrelor, n (%) 6 (0.4) 1 (0.1) 2 (0.1) 4 (1.6)
  Heparin, n (%)* 157 (8.6) 11 (1.0) 25 (1.6) 132 (46.6)
  Cardiology referral, n (%) 888 (47.9) 378 (34.8) 627 (40.2) 261 (89.7)
Investigation and management in ≤30 days of presentation
Echocardiography, n (%) 183 (9.5) 36 (3.2) 90 (5.5) 93 (31.4)
Coronary angiography, n (%) 220 (11.4) 24 (2.1) 72 (4.4) 148 (50.0)
Percutaneous coronary 
intervention, n (%)
138 (7.1) 9 (0.8) 36 (2.2) 102 (34.5)
*Including unfractionated or low-molecular-weight heparin.
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addition of clinical risk scores. We make a number of 
clinically relevant observations.
When used in isolation, the ESC pathway identifies a 
high proportion of patients as low-risk, but the NPV and 
sensitivity were poor, missing 27 index or 30-day events. 
The addition of a clinical risk score markedly improves 
safety, with the combination of ESC pathway and a 
HEART score ≤3 missing just 1 index event. However, this 
strategy identifies 3-fold fewer patients as low-risk. Con-
versely, the High-STEACS pathway incorporates a lower 
threshold of 5 ng/L to rule out myocardial infarction and 
has both a high NPV and sensitivity, missing just 3 index 
or 30-day events and identifying two-thirds of patients 
as low-risk. There was no improvement in diagnostic per-
formance when the High-STEACS pathway was applied 
in conjunction with the TIMI, GRACE, EDACS, or HEART 
scores, but there was a 2- to 3-fold reduction in the pro-
portion of patients identified as low-risk.
The ESC 3-hour pathway was first introduced in the 
2011 NSTE-ACS guideline (Non-ST Elevation Acute Cor-
onary Syndrome) and has been a central component of 
our evaluation of patients with suspected acute coro-
nary syndrome.4,18 This pathway was devised in an era of 
contemporary cardiac troponin assays, where the upper 
reference limit was ≤5-fold higher than that applied with 
current generation high-sensitivity assays.23 It is perhaps 
unsurprising that when evaluated with more sensitive 
assays, the diagnostic performance of this pathway is 
worse. Several recent studies have demonstrated a low 
NPV, with diagnostic sensitivities <95%, well below the 
level deemed clinically acceptable.5–7 Although the ESC 
guideline includes a low-risk GRACE score (≤140) as 
Figure 3. Distribution of patients per risk category assigned by the TIMI, GRACE, EDACS, and HEART risk scores in the analysis population.  
EDACS indicates Emergency Department Assessment of Chest Pain Score; GRACE, Global Registry of Acute Coronary Events; HEART, History, ECG, Age, Risk 
factors, Troponin; and TIMI, Thrombolysis In Myocardial Infarction.
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a final step before discharge, there is a lack of clarity 
as to the intended strategy for this approach in clinical 
practice. In the present analysis, we demonstrate that a 
GRACE score ≤140 is not effective, but a more conser-
vative GRACE score of ≤108 does improve the NPV and 
sensitivity, although the latter remained at 96%.
The GRACE and TIMI scores were derived in pa-
tients with confirmed myocardial infarction and were 
designed to guide prognostication and management. 
These scores have been extrapolated for use as risk 
stratification tools in patients with suspected acute cor-
onary syndrome, and both improved the performance 
of the ESC pathway. In contrast, both the HEART and 
EDACS scores were derived and validated in patients 
with suspected, not confirmed, myocardial infarction.
The HEART score has been shown to perform better 
than GRACE and TIMI in patients with suspected acute 
coronary syndrome.11 In this analysis, we demonstrate 
the greatest improvement in the safety of the ESC path-
way when a HEART score of ≤3 was included. The ESC 
pathway and the HEART score appear synergistic, with 
the combination of strategies offering a better safety 
profile than either in isolation. Our observation is con-
sistent with a recent meta-analysis of 11 217 patients 
with suspected acute coronary syndrome, in whom a 
HEART score ≤3 gave a sensitivity of 96.7%.24 The cur-
rent HEART score uses troponin as a categorical variable 
based on multiples of the upper reference limit. One 
option to improve the performance of the HEART score 
further would be to incorporate high-sensitivity cardiac 
troponin concentrations as a continuous marker of risk4 
and to harness rather than omit this information to aid 
risk stratification. Similar improvements in the safety of 
the ESC pathway were observed when applied in con-
junction with a low-risk EDACS score. However, this 
approach identified almost twice as many patients as 
low-risk. This observation may influence clinicians when 
considering which approach to implement in practice.
The High-STEACS pathway applies a cardiac tropo-
nin threshold of <5 ng/L in conjunction with a nonisch-
emic ECG as an initial risk stratification step, with serial 
testing at 3 hours in all other patients. This pathway 
performs well in patients with suspected acute coro-
nary syndrome, and we demonstrate no improvement 
Table 3. Diagnostic Metrics for the European Society of Cardiology 3-Hour Pathway With and Without Clinical Risk Scores
Variable
True 
Positive
False 
Positive
True 
Negative
False 
Negative
Negative 
Predictive 
Value (95% 
CI)
Sensitivity 
(95% CI)
Positive 
Predictive 
Value (95% 
CI)
Specificity 
(95% CI)
Proportion 
Low-Risk 
(%)
ESC 3-h pathway 244 314 1301 27 97.9 
(97.1–98.6)
89.9 
(86.3–93.4)
43.7 
(39.7–47.9)
80.5 
(78.6–82.5)
70.4
ESC 3-h + TIMI (0/1) 265 777 838 6 99.2 
(98.5–99.7)
97.6 
(95.5–99.1)
25.5 
(22.9–28.1)
51.9 
(49.5–54.3)
44.8
ESC 3-h + GRACE ≤108 262 700 915 9 99.0 
(98.2–99.5)
96.5 
(94.0–98.3)
27.3 
(24.5–30.1)
56.7 
(54.2–59.1)
49.0
ESC 3-h + EDACS <16 265 821 794 6 99.2
 (98.5–99.7)
97.6 
(95.5–99.1)
24.4 
(21.9–27.0)
49.2 
(46.7–51.6)
42.4
ESC 3-h + HEART ≤3 270 1148 467 1 99.7 
(99.0–100)
99.4 
(98.3–100)
19.1 
(17.1–21.1)
28.9 
(26.7–31.2)
24.8
ESC indicates European Society of Cardiology; EDACS, Emergency Department Assessment of Chest Pain Score; GRACE, Global Registry of Acute Coronary 
Events; HEART, History, ECG, Age, Risk factors, Troponin; and TIMI, Thrombolysis In Myocardial Infarction.
Table 4. Diagnostic Metrics for the High-STEACS Pathway With and Without Clinical Risk Scores
Variable
True 
Positive
False 
Positive
True 
Negative
False 
Negative
Negative 
Predictive 
Value (95% 
CI)
Sensitivity 
(95% CI)
Positive 
Predictive 
Value (95% 
CI)
Specificity 
(95% CI)
Proportion 
Low-Risk 
(%)
High-STEACS Pathway 273 400 1241 3 99.7 
(99.4–99.9)
98.7 
(97.4–99.8)
40.6 
(36.9–44.3)
75.6 
(73.5–77.7)
64.9
High-STEACS + TIMI (0/1) 275 808 833 1 99.8 
(99.4–100)
99.5 
(98.3–100)
25.4
 (22.9–28)
50.8
 (48.3–53.2)
43.5
High-STEACS + GRACE ≤108 274 734 907 2 99.7 
(99.3–100)
99.1 
(97.7–99.8)
27.2
 (24.5–30)
55.3 
(52.9–57.7)
47.4
High-STEACS + EDACS <16 274 851 790 2 99.7 
(99.2–99.9)
99.1 
(97.7–99.8)
24.4 
(21.9–26.9)
48.1 
(45.7–50.6)
41.3
High-STEACS + HEART ≤3 276 1176 465 0 99.9 
(99.6–100)
99.8 
(99.3–100)
19.0 
(17.1–21.1)
28.3
 (26.2–30.6)
24.3
EDACS indicates Emergency Department Assessment of Chest Pain Score; GRACE, Global Registry of Acute Coronary Events; HEART; High-STEACS, High-
Sensitivity Troponin in the Evaluation of Patients with Acute Coronary Syndrome; and TIMI, Thrombolysis In Myocardial Infarction. 
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in safety with the addition of clinical risk scores. When 
applied in isolation, the High-STEACS pathway ruled 
out 1244 patients with 3 missed events (a miss rate of 
<1 in 400 patients). The safety of pathways incorpo-
rating low concentrations of cardiac troponin for risk 
stratification is high and not improved by additional risk 
scores. One of the reasons this approach is so effective 
is that cardiac troponin concentrations are increased in 
patients with risk factors for acute coronary syndrome 
(such as hyperlipidemia, hypertension, or renal impair-
ment) or in those with subclinical coronary or structural 
heart disease that may not be evident at presentation 
to the emergency department.13,25–27
There are several alternatives to the 2 rule-out path-
ways presented in this analysis.28 The ESC introduced 0- 
and 1-hour rule-out pathways in their 2015 guideline.4 
This pathway has excellent diagnostic performance and 
has been validated in a number of settings, including 
a subgroup analysis of the present study.29–33 Howev-
er, the practicality of delivering presentation troponin 
results and obtaining serial testing at 1 hour may be 
challenging in many healthcare settings. Until point-
of-care solutions facilitate rapid turnaround times with 
similar test characteristics to laboratory troponin assays, 
safe alternative pathways with serial testing at 2 or 3 
hours are required. In such settings, we believe the ESC 
3-hour pathway should be applied with a clinical risk 
score. Alternatively, the EDACS score alone provides ex-
cellent safety and efficacy when applied with a nonisch-
emic ECG and serial cardiac troponin testing at 0 and 2 
hours, as recommended by the authors (Table VII in the 
online-only Data Supplement).20
In settings where high-sensitivity cardiac troponin 
I testing is available, the High-STEACS pathway is a 
more effective alternative approach, identifying more 
patients as low-risk without compromising safety. The 
performance of this pathway is currently being evalu-
ated in a stepped-wedge cluster randomized trial of 
≈30 000 patients in Scotland (NCT03005158).
There are important limitations to the data present-
ed. This is a single-center observational cohort study. 
However, as a large tertiary cardiology center, we be-
lieve our findings are likely to be generalizable. The 
High-STEACS pathway was derived in the first 1218 pa-
tients included in this population. Although the perfor-
mance was identical in our sensitivity analysis excluding 
these patients, further external validation studies are 
required. Because the majority of patients underwent 
serial sampling at 3 hours (Table IX in the online-only 
Data Supplement), we were only able to evaluate the 
ESC 1-hour pathway in a minority of patients. Because 
this strategy includes low concentrations of cardiac tro-
ponin to risk-stratify patients, it is likely that the perfor-
mance would be similar to the High-STEACS pathway 
in the full population. To date, no comparison studies of 
these approaches have been undertaken. We were not 
able to undertake evaluation of other validated rule-
out pathways such as ADAPT (Accelerated Diagnostic 
Protocol to Assess Patients With Chest Pain Symptoms 
Using Contemporary Troponins as the Only Biomarker) 
or T-MACS (Troponin only Manchester Acute Coro-
nary Syndrome score). Our analysis of the ESC 3-hour 
pathway focused on high-sensitivity cardiac troponin 
I. However, similar findings have been documented in 
studies of high-sensitivity cardiac troponin T.5 Finally, as 
with all observational cohort studies, no patients were 
discharged on the basis of the pathways evaluated, and 
differences in management may have influenced out-
comes. Although we did not have information on rates 
of exercise tolerance testing or nuclear testing, patients 
Figure 4. Proportion of patients classified as low-risk on the basis of the ESC 3-hour or High-STEACS pathway alone or in combination with the 
TIMI, GRACE, EDACS, or HEART scores.  
ESC indicates European Society of Cardiology; EDACS, Emergency Department Assessment of Chest Pain Score; GRACE, Global Registry of Acute Coronary Events; 
HEART, History, ECG, Age, Risk factors, Troponin; High-STEACS, High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome; and TIMI, 
Thrombolysis In Myocardial Infarction. 
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with low troponin concentrations were less likely to 
undergo transthoracic echocardiography or invasive 
coronary angiography (Table 2). When we repeated the 
primary analysis removing all patients who underwent 
these investigations (Table VI in the online-only Data 
Supplement), we observed no reduction in safety. Nev-
ertheless, the results of implementation studies are nec-
essary to guide clinical practice and future guidelines.
CONCLUSIONS
Clinical risk scores significantly improve the safety of the 
ESC 3-hour pathway that relies on the 99th percentile 
to rule out myocardial infarction. Where lower cardiac 
troponin concentrations are used to rule out myocardial 
infarction, as applied in the High-STEACS pathway, risk 
scores halve the proportion of patients ruled out with-
out further improvements in safety.
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